ArticleOncology research2026
Adenoid Cystic Carcinoma of the Breast: Clinicopathological Features and Long-Term Outcomes from a 20-Year Retrospective Cohort.
Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenoid cystic carcinoma (ACC) of the breast is a rare triple-negative malignancy with an indolent clinical course distinct from conventional triple-negative breast cancer (TNBC). Optimal management remains undefined due to limited prospective data. This study aimed to characterise the clinicopathological features, treatment patterns, and long-term outcomes of breast ACC at a high-volume specialist centre, contributing real-world evidence to inform management in the absence of prospective trial data.
methodsA single-institution retrospective cohort study was conducted of 24 patients with histopathologically confirmed breast ACC treated at The Royal Marsden NHS Foundation Trust between 2000 and 2020. Clinicopathological and outcome data were analysed descriptively; overall survival (OS), disease-specific survival (DSS), and relapse-free survival (RFS) were estimated using the Kaplan-Meier method.
resultsMedian age was 57 years. Nodal involvement was rare (8%). Adjuvant radiotherapy was administered in 88% of patients; only two patients (8%) received chemotherapy for breast ACC. Five patients (21%) experienced disease relapse after a median of 2.3 years (range 1.3-14.0). The estimated 5- and 10-year OS were both 88.4% (95% CI 74.5-100%) and DSS were both 93.3% (95% CI 81.5-100%).
conclusionsTo our knowledge this represents the largest single-institution cohort study of breast ACC reported to date. The clinical behaviour of breast ACC more closely resembles salivary gland ACC than conventional TNBC, supporting a conservative locoregionally focused management approach and questioning the routine use of chemotherapy on the basis of triple-negative receptor status alone. The propensity for late relapse supports long-term surveillance beyond the standard 5-year window.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.